ReviewUrologic oncology2021

Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.

Peter Makhov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.